Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06103760
Other study ID # 2023/PID01587
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 31, 2023
Est. completion date January 15, 2026

Study information

Verified date May 2024
Source Royal North Shore Hospital
Contact Erica Bell
Phone 02 9462 9905
Email NSLHD-researchpoet@health.nsw.gov.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: - to investigate whether Esketamine is effective when added to ongoing antidepressant treatment - to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice Participants will: - attend the clinic for supervised self-administration of intranasal Esketamine treatment - be observed for 2 hours following Esketamine administration including blood pressure monitoring - be asked to complete a battery of questionnaires - be reimbursed for travel expenses


Description:

Depression is a common mental illness, and it is one of the leading causes of disease burden worldwide. Fortunately, there are many effective treatments available for depression, including lifestyle changes, psychological treatments, and medications such as antidepressants. However, not all patients will respond to the first treatment prescribed. Some patients may only experience a 'partial response', where a few treatments help their depression somewhat, but they do not achieve a full recovery. Currently, the reasons why some patients do not respond, or only experience a partial response to an antidepressant, is not fully understood. Recently, researchers have been investigating new medications that may help patients recover from depression. One of these new medications is Esketamine, which is a relatively new molecule derived from a drug called Ketamine - an anaesthetic that has been used medically for decades. Researchers have been investigating the antidepressant properties of Ketamine for a long time. It is thought that Ketamine, and its derivative, Esketamine, help to treat depression for a number of reasons. However, it is not yet known which patients benefit most from Esketamine when used in conjunction with conventional antidepressants. In addition, we do not yet understand how the effect of Esketamine is impacted by other treatments that a patient may be taking for their depression. Finally, it has not yet been investigated how patients with a partial response to an antidepressant will benefit from adding Esketamine to their therapeutic regimen without switching to a new baseline antidepressant. Therefore, there are two principle aims of this study 1) to investigate whether Esketamine is effective when added to ongoing antidepressant treatment and 2) to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice.


Recruitment information / eligibility

Status Recruiting
Enrollment 162
Est. completion date January 15, 2026
Est. primary completion date September 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Adults aged 18-65 years old 2. Diagnosis of Major Depressive Disorder (MDD) 3. Currently depressed 4. Had an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration) 5. Be maintained on their current antidepressant medication or psychological therapy at the time of enmrolment 6. Able to understand and provide informed consent Exclusion Criteria: 1. Concurrent diagnoses: - Participants with other 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-5) e.g., current substance misuse disorder, bipolar disorder, schizophrenia - Participants who are unable to understand the study and therefore unable to provide informed consent 2. Pregnancy: - Participants who are pregnant and/or breastfeeding - Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods 3. Current medications: - Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam - Participants on complementary and alternative medicine therapies i.e., St John's wort, Chinese medicines, and various herbal and homeopathic treatments 4. Stimulants - Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study. - Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure. 5. Medical history: - Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary) - Participants with a history of uncontrolled hypertension - Participants with uncontrolled diabetes mellitus - Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage - Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery - Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month. 6. Substance Misuse History: - Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamphetamine (MDMA), or other hallucinogen use history - Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients

Study Design


Intervention

Drug:
Esketamine Nasal Spray [Spravato]
This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

Locations

Country Name City State
Australia Royal North Shore Hospital St Leonards New South Wales

Sponsors (2)

Lead Sponsor Collaborator
Royal North Shore Hospital Janssen-Cilag Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of treatment responders determined by a 50% reduction on the Hamilton Depression Rating Scale (HAM-D) 17-Item scoring. Hamilton Depression Rating Scale (HAM-D) 17-Item scoring At the end of week 4
Primary Mean depression score on the Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item. Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item. Baseline, at the end of weeks 1,2,3, and 4 (primary time point); and further after week 8 and week 12 after Esketamine was commenced.
Primary Global functioning determined by Clinical Global Impression (CGI) score. Clinical Global Impression (CGI) Baseline, week 1, week 2, week 3, week 4 (primary time point), week 8 and week 12 after Esketamine was commenced.
Secondary Change in mood symptom scores assessed using the visual analogue scale (self-reported) Visual analogue scale (self-reported) Baseline, after treatment day 1 and day 3 of each week until Esketamine is ceased.
Secondary Depressive symptoms assessed using the Beck Depression Inventory (BDI) 21-Item. Beck Depression Inventory (BDI) 21-Item. Baseline and at week 4 after Esketamine was commenced.
Secondary Anxiety symptoms assessed using the State-Trait Anxiety Inventory (STAI) State-Trait Anxiety Inventory (STAI) Baseline and at week 4 after Esketamine was commenced.
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4